Prelude Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Prelude Therapeutics (PRLD).

Price Target Range — 10 Quarters

Analyst Consensus — 7 Analysts

3S.Buy

3Buy

1Sell

Consensus RatingMarket Outperform# Analysts7Avg. Consensus PT$6Upside to Avg. PT+70.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 17, 2026	JP Morgan	Joyce Zhou	Initiate	Overweight	$12
Jul 29, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$8
May 4, 2026	D. Boral Capital	Jason Kolbert	Initiate	Buy	$9
Apr 27, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$5→$8
Mar 11, 2026	Citizens	Reni Benjamin	PT Raise	Market Outperform	$3→$6
Sep 23, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$5
Aug 18, 2025	JMP Securities	Reni J. Benjamin	PT Cut	Market Outperform	$4→$3
May 5, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$5
Apr 29, 2025	JMP Securities	Reni Benjamin	Maintained	Market Outperform	$4
Apr 8, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$5
Mar 12, 2025	Citizens Capital Markets	Reni Benjamin	Maintained	Market Outperform	$4
Dec 11, 2024	JMP Securities	Reni Benjamin	PT Cut	Market Outperform	$7→$4
Nov 8, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$5
Oct 28, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$5
Sep 19, 2024	HC Wainwright & Co.	Robert Burns	Upgrade	Neutral→Buy	$5
Sep 16, 2024	JMP Securities	Reni Benjamin	Maintained	Market Outperform	$7
Sep 16, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$5
Sep 10, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$5
Aug 15, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$5
Mar 13, 2024	JMP Securities	Reni Benjamin	Initiate	Market Outperform	$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12

JP Morgan analyst Joyce Zhou initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Overweight rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

D. Boral Capital analyst Jason Kolbert initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Buy rating and announces Price Target of $9.

Benzinga Newsdesk

Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmark, HC Wainwright, Stifel, B of A Sec, Mizuho updated their ratings and price targets.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and raises the price target from $5 to $8.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

Citizens analyst Reni Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and raises the price target from $3 to $6.

Benzinga Newsdesk

Prelude Therapeutics Inc

Prelude Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12

PRO
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target

PRO
D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday

PRO
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

PRO
Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

People Also Watch

People Also Watch

Prelude Therapeutics Inc

Prelude Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12

PROHC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target

PROD. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday

PROHC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

PROCitizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

People Also Watch

People Also Watch

PRO
JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12

PRO
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target

PRO
D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

PRO
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

PRO
Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6